Clinical Trial Update: A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 study comparing SB17, a proposed ustekinumab biosimilar, to Stelara in adults with moderate-to-severe plaque psoriasis; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• SB17 (ustekinumab biosimilar)
• Stelara (ustekinumab)

Snippet

Sponsor: Samsung Bioepis Co., Ltd. | Conditions: Psoriasis, Moderate to Severe Plaque Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2025-05-25